Use of estrogen antagonists and aromatase inhibitors in endometriosis

Paola Viganò, Silvia Mangioni, Maria Paola Odorizzi, Annalisa Chiodini, Sabrina Rocca, Ilda Chiodo

Research output: Contribution to journalArticlepeer-review


Endometriosis is an estrogen-dependent disorder mostly occurring in reproductive-age women. Various therapies have been used in an attempt to treat endometriosis, including ovarian suppression therapy, surgical treatment or a combination of these strategies. However, in general, substantial surgery remains the primary treatment option for endometriosis at all stages. Recently, aromatase inhibitors and anti-estrogens have been proposed as novel potential candidates. The rationale for the use of aromatase inhibitors is mostly related to the high aromatase expression in endometriotic cysts and extra-ovarian endometriotic implants. Among anti-estrogens, raloxifene has been investigated in animal models with good results, but in premenopausal women, the compound does not seem to suppress estrogen production.

Original languageEnglish
Pages (from-to)1209-1212
Number of pages4
JournalCurrent Opinion in Investigational Drugs
Issue number10
Publication statusPublished - Oct 2003


  • Anti-estrogens
  • Aromatase inhibitors
  • Endometriosis
  • Estrogen antagonists
  • Letrozole
  • Raloxifene
  • SERM

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'Use of estrogen antagonists and aromatase inhibitors in endometriosis'. Together they form a unique fingerprint.

Cite this